To determine the dose of triptorelin that is sufficient to maintain complete ovarian suppression in female patients with childhood-onset systemic lupus erythematosus ( SLE ) who require cyclophosphamide therapy , to determine the length of time needed to achieve ovarian suppression after initiation of triptorelin treatment , and to investigate the safety of triptorelin .